Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intensive Home BP control

PreclinicalSmall molecule

SShanghai Institute of Hypertension

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Home Blood PressureRecruiting

Home Blood PressurePreclinical

Recruiting

Timeline

Expected Milestones

Q2 2030

Home Blood Pressure

NCT05858944

Clinical

Trials by Indication[1]

Home Blood Pressure1 trial

Home Blood Pressure Intervention in the Community Trial

Recruiting·SShanghai Institute of Hypertension·N/A·NCT05858944·10,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intensive Home BP control. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intensive Home BP control compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intensive Home BP control. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Institute of Hypertension company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Institute of Hypertension

Related News